Hans Rittmannsberger
Overview
Explore the profile of Hans Rittmannsberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rittmannsberger H, Barth M, Lamprecht B, Malik P, Yazdi-Zorn K
Neuropsychiatr
. 2023 Dec;
38(1):1-23.
PMID: 38055146
An infection with SARS-CoV‑2 can affect the central nervous system, leading to neurological as well as psychiatric symptoms. In this respect, mechanisms of inflammation seem to be of much greater...
2.
Rittmannsberger H, Barth M, Malik P, Zorn-Yazdi K
Psychiatr Danub
. 2023 Nov;
35(4):622-627.
PMID: 37992115
The SARS-CoV-2 pandemic exerted an unprecedented threat to the population worldwide. This led to a sharp increase in symptoms of depression, anxiety, and PTSD, especially in the early phase of...
3.
Rabady S, Hoffmann K, Aigner M, Altenberger J, Brose M, Costa U, et al.
Wien Klin Wochenschr
. 2023 Aug;
135(Suppl 4):525-598.
PMID: 37555900
These S1 guidelines are an updated and expanded version of the S1 guidelines on long COVID differential diagnostic and management strategies. They summarize the state of knowledge on postviral conditions...
4.
Rittmannsberger H, Barth M, Malik P, Malsiner-Walli G, Yazdi K
Acta Neuropsychiatr
. 2022 Mar;
34(6):289-310.
PMID: 35357298
Objective: Since the onset of COVID-19 pandemic, many case reports and case series dealt with new-onset psychotic disorders in patients either infected with Our aim was to provide a comprehensive...
5.
Rabady S, Altenberger J, Brose M, Denk-Linnert D, Fertl E, Gotzinger F, et al.
Wien Klin Wochenschr
. 2021 Dec;
133(Suppl 7):237-278.
PMID: 34851455
This guideline comprises the state of science at the time of the editorial deadline. In view of the high turnover of knowledge the guideline is designed as a living guideline....
6.
Rittmannsberger H, Barth M, Malik P, Yazdi K
Fortschr Neurol Psychiatr
. 2021 Aug;
90(3):108-120.
PMID: 34341978
The SARS-CoV-2 virus (Severe Acute Respiratory Syndrome Coronavirus Type 2) and COVID-19 (Coronavirus Disease 2019) can affect numerous organ systems. In the present paper we offer an overview of the...
7.
Rittmannsberger H
Psychiatr Danub
. 2019 Jul;
31(2):148-156.
PMID: 31291218
Amisulpride (AMS) in low dosage has been used effectively for treatment of dysthymia. Yet there is a dearth of reports on its use as an augmentation agent in therapy-resistant depression....
8.
Barth M, Dunzinger A, Wimmer I, Winkler J, Rittmannsberger H, Nader M, et al.
Q J Nucl Med Mol Imaging
. 2018 Jun;
64(2):203-210.
PMID: 29916219
Background: More than 50% of patients with major depressive episode (MDE) fail to respond to initial treatment with first line pharmacological therapy. Altered receptor and serotonin transporter function are considered...
9.
Rittmannsberger H, Rosenleitner J, Malsiner-Walli G, Werl R, Rittmannsberger B, Yazdi K
J Clin Psychopharmacol
. 2017 Feb;
37(2):250-254.
PMID: 28195930
Purpose: Long-acting injectable (LAI) antipsychotics are recommended especially for patients with multiple admissions and poor adherence. The empirical basis of this strategy is a matter of debate. Methods: In a...
10.
Fleischhacker W, Hofer A, Jagsch C, Pirker W, Psota G, Rittmannsberger H, et al.
Neuropsychiatr
. 2016 Sep;
30(3):123-130.
PMID: 27580887
Tardive dyskinesia (TD) remains a relevant clinical problem despite the increasing use of new-generation antipsychotics. Antipsychotic-induced tardive syndromes are difficult to treat and have a low tendency of remission. Therefore,...